Stay updated on Pembrolizumab and Olaparib in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab and Olaparib in NSCLC Clinical Trial page.

Latest updates to the Pembrolizumab and Olaparib in NSCLC Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedAn administrative update adds Revision: v3.4.2 to the history and removes the earlier funding/operating-status notice, reflecting system maintenance rather than study content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check21 days agoChange DetectedSite-wide notice about government funding lapse was added, and the page revision updated to v3.4.1 (replacing v3.4.0).SummaryDifference0.3%

- Check28 days agoChange DetectedUI tweaks include showing the glossary, explaining color-coded highlights, and updating the revision label to v3.4.0; a capitalization change from 'No FEAR Act data' to 'No FEAR Act Data' was made.SummaryDifference0.3%

- Check42 days agoChange DetectedThe page history now includes an entry for Revision: v3.3.4 and the entry for Revision: v3.3.3 was removed.SummaryDifference0.0%

- Check63 days agoChange DetectedNew revision entry 'Revision: v3.3.3' was added. 'HHS Vulnerability Disclosure' and 'Revision: v3.3.2' were removed from the deletions list.SummaryDifference0.1%

- Check92 days agoChange DetectedAdded Revision: v3.3.2 and removed Revision: v3.2.0 along with government funding notices; these changes update site metadata rather than the study details.SummaryDifference0.3%

Stay in the know with updates to Pembrolizumab and Olaparib in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab and Olaparib in NSCLC Clinical Trial page.